Findings from the study showed 44% of patients treated with berubicin experienced a statistically significant improvement in progression free survival.
The application is supported by data from 2 pivotal open-label, randomized phase 3 trials (SIOPEL 6 and ACCL0431), which compared the efficacy of sodium thiosulfate plus cisplatin to cisplatin alone for the prevention of cisplatin-induced hearing loss.
Maximal resection of a contrast-enhanced (CE) tumor is associated with improved overall survival in patients with isocitrate dehydrogenase gene 1 or 2 (IDH)-wild-type and IDH-mutant subtype glioblastomas.
A novel workflow that combines advanced optical imaging with an artificial intelligence algorithm may accurately diagnose brain tumors in real time in the operating room.